Roche takes 'leap of faith' with $20M bet on C4T’s antibody-targeted protein degraders ino.to/6xOeu9R
Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 million upfront and committing more than $1 billion in milestones | Roche has joined Big Pharma peers in the emerging degrader-antibody conjugate space, paying C4 Therapeutics $20 million upfront and committing more than $1 billion in milestones to partner on two oncology targets.
